Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Purpose
This is a Phase 1b/2 study of AVB-S6-500 designed to evaluate the safety and efficacy of AVB-S6-500 in combination with cabozantinib, AVB-S6-500 in combination with cabozantinib and nivolumab and AVB-S6-500 monotherapy in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC). The phase 1b portion of the study is open label and patients with advanced ccRCC who had progressed on or after at least one prior line of treatment will receive AVB-S6-500 + cabozantinib. Two dose levels will be evaluated. The Phase 2 portion of the study is open-label 3-part study to evaluate efficacy and tolerability of AVB-S6-500 + cabozantinib, AVB-S6-500 + cabozantinib + nivolumab, and AVB-S6-500 alone.
Condition
- Clear Cell Renal Cell Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age 18 years or older - Histologically confirmed advanced or metastatic clear cell Renal Cell Carcinoma confirmed by imaging. Phase 1b and Phase 2 Part A: has progressed on/after at least one front-line of treatment; Phase 2 Part B: No prior systemic treatment; Phase 2 Part C: not amenable to curative intent therapy. - Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 28 days of enrollment - Must have at least one measurable lesion according to RECIST 1.1 - ECOG performance status of 0-1 - Adequate bone marrow, liver and kidney function - Life expectancy of >12 weeks - At least 28 days between termination of prior major surgery or anticancer therapy or 14 days from last radiation therapy and administration of AVB-S6-500
Exclusion Criteria
- Received prior treatment with cabozantinib (Phase1b and Phase 2 Part A) - Received prior treatment with nivolumab (Phase 2 Part B) - Concurrent anti-cancer therapy or any other interventional treatment or other interventional research trial - History of prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast - Symptomatic CNS metastasis or metastases - Active GI disease that would impact absorption of cabozantinib - Nephrotic range proteinuria at screening - Evidence of pleural effusion, ascites etc that requires therapeutic intervention within 28 days prior to AVB-S6-500 administration - Phase 2 Part A and Part B: Has had a major bleed in the last 3 months, uncontrolled hypertension despite treatment with antihypertensives or is not appropriate for treatment with cabozantinib in the Investigator's opinion - Serious active infection requiring IV antibiotics and/or hospitalization at study entry - Phase 2 Part B: Has active, known or suspected autoimmune disease, defined as requiring systemic treatment - Active COVID-19, HIV, Hepatitis B or Hepatitis C virus.
Study Design
- Phase
- Phase 1/Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Phase 1b: Batiraxcept + cabozantinib |
Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated. |
|
|
Experimental Phase 2 Part A: batiraxcept + cabozantinib |
One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated. |
|
|
Experimental Phase 2 Part B: batiraxcept + cabozantinib + nivolumab |
One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab. |
|
|
Experimental Phase 2 Part C: batiraxcept alone |
One dose level of batiraxcept administered Q2W will be evaluated. |
|
More Details
- Status
- Terminated
- Sponsor
- Aravive, Inc.